Lyell Immunopharma (LYEL) Other Working Capital Changes (2021 - 2026)
Lyell Immunopharma (LYEL) reported Other Working Capital Changes of $10000.0 for Q1 2026, up 108.93% on a YoY basis from $4786.3 in Q1 2025, and up 100.46% sequentially from -$2.2 million in Q4 2025.
Lyell Immunopharma (LYEL) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 6 years of Other Working Capital Changes data on file, last reported at $10000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Working Capital Changes rose 108.93% year-over-year to $10000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.6 million (down 537.56% YoY), and the FY2025 full-year result was -$2.7 million, down 565.69% from the prior year.
- Other Working Capital Changes climbed to $10000.0 in Q1 2026, from -$2.2 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $2.4 million in Q4 2025 to a low of -$3.6 million in Q4 2024.
- A 5-year average of -$343823.5 and a median of -$90000.0 in 2026 frame the typical range for Other Working Capital Changes.
- Across the five-year window, Other Working Capital Changes surged 234.73% in 2022 and slumped 593.59% in 2025, its largest moves.
- Tracing LYEL's Other Working Capital Changes over 5 years: stood at -$3.8 million in 2022, then jumped by 97.04% to -$112000.0 in 2023, then sank by 178.57% to -$312000.0 in 2024, then tumbled by 593.59% to -$2.2 million in 2025, then jumped by 100.46% to $10000.0 in 2026.
- Business Quant data shows LYEL's Other Working Capital Changes at $10000.0 in Q1 2026, -$2.2 million in Q4 2025, and -$349000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | -2.16 Mn |
| Dec 31, 2025 | -2.16 Mn |
| Dec 31, 2025 | -2.16 Mn |
| Sep 30, 2025 | -349,000.00 |
| Sep 30, 2025 | -349,000.00 |
| Sep 30, 2025 | -349,000.00 |
| Jun 30, 2025 | -111,000.00 |
| Jun 30, 2025 | -111,000.00 |
| Jun 30, 2025 | -111,000.00 |
| Mar 31, 2025 | -112,000.00 |
| Mar 31, 2025 | -112,000.00 |
| Mar 31, 2025 | -112,000.00 |
| Dec 31, 2024 | -312,000.00 |
| Dec 31, 2024 | -312,000.00 |
| Dec 31, 2024 | -312,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Sep 30, 2024 | 126,000.00 |